Medindia

X

BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer

Tuesday, October 23, 2007 General News J E 4
Advertisement
BRISBANE, Calif., Oct. 22 BiPar Sciences, Inc., aprivately held biopharmaceutical company developing novel cancer therapies,today announced that key data supporting its PARP (poly-ADP-ribose polymerase)inhibitor drug development programs will be presented at the AmericanAssociation for Cancer Research-National Cancer Institute-EuropeanOrganization for Research and Treatment of Cancer (AACR-NCI-EORTC)International Conference on Molecular Targets and Cancer Therapeutics in SanFrancisco from Oct. 22 to 26 and the EORTC-NCI-ASCO Annual Meeting on"Molecular Markers in Cancer" in Brussels, Nov. 15 to 17.

PARP is a novel, validated target for cancer treatment. PARP1 plays acentral role in cell proliferation and in DNA repair. BiPar scientists willpresent results showing that PARP1 gene expression is significantlyupregulated in many but not all tumor types. BiPar's novel, proprietary PARPinhibitors are members of a new generation of drug candidates that showpromising activity and a favorable toxicity profile. Preclinical studiessuggest the drugs selectively inhibit tumor cell proliferation and are activeagainst a broad range of tumor types. BiPar is initiating Phase 1b and Phase 2clinical trials of BSI-201, its lead PARP inhibitor, in several major cancers.That research program has been directed in large part by the molecularbiomarker data being presented at these meetings.

"These findings will focus our efforts on those tumor types with thegreatest opportunity for clinical success," said Barry Sherman, M.D., BiPar'sexecutive vice president. "With this information we believe we will be able toefficiently exploit our pipeline of PARP inhibitors that target major unmetneeds in cancer."

About BiPar Sciences

BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stagebiopharmaceutical company developing and commercializing a pipeline of novel,tumor-selective drugs designed to meet the significant unmet needs of cancerpatients.The schedule of presentations is as follows: Title: The novel PARP-1 inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotopic activity in human pancreatic cancer When: Wednesday, Oct. 24, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Davide Melisi, M.D., Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center Title: PARP-1 gene over-expression in primary human cancers: A potential marker for PARP inhibition. When: Thursday, Oct. 25, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar Title: The PARP1 gene is over-expressed in triple negative breast cancer When: Thursday, Nov. 15, 6 to 8 p.m. CEST Where: EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer," Sheraton Brussels, Hotel & Towers, Brussels, Belgium Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar

SOURCE BiPar Sciences, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PLC Medical Systems to Introduce RenalGuard(TM) at...
S
Windswept Environmental Group, Inc. Announces Succ...